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ABSTrACT
Almost ten years have passed since the identification of Kv7.2 and Kv7.3, the genes 
altered in Benign Familial Neonatal Seizures (BFNS), a familial autosomal dominant 
focal epilepsy of the newborn. Despite the rarity of the disease, clinical and genetic data 
have been gathered from more than 50 BFNS‑affected families; these studies reveal that 
each family harbours a specific disease‑causing mutation, and that the mutation‑induced 
functional changes range from a subtle alteration in channel  behaviour to a complete 
ablation of channel function. Prompted by the recent identification of peculiar gating 
changes in Kv7.2 subunits caused by novel mutations responsible for BFNS, in the present 
work we attempt to link, whenever possible, the specific genetic defect with the clinical 
evolution of the disease in the affected families on one side, and, on the other, with the 
functional defects revealed by expression studies. Such genotype‑phenotype  correlations 
may provide clues on the pathogenesis of the wide variety of  neuropsychiatric 
 manifestations often associated to BFNS, and should further our attempts to gain 
more detailed functional information which might help to elucidate the  pathogenetic 
 mechanisms of the disease.
Neonatal seizures with a strong familial component were first described in 1964,1 
revealing that genetic mechanisms, in addition to environmental perinatal factors, contrib-
uted to disease pathogenesis. The term benign was added few years later, in recognition of 
the fact that most of the patients display a normal psychomotor development.2 Currently, 
Benign Familial Neonatal Seizures (BFNS; OMIM #121200) are classified within the 
group of familial autosomal dominant focal epilepsies;3 in BFNS patients, convulsions 
begin around day 3 and disappear spontaneously around the third month of postnatal 
life.4 More recent follow-up studies reveal that seizures or other neuropsychiatric abnor-
malities can occur in up to 15% of the patients, therefore questioning the benignity of 
the disease.5
In 1989, the first locus associated to BNFS was identified (20q13.3, EBN1); a second 
locus (8q24, EBN2) was subsequently discovered. Using positional cloning strategies, the 
genes altered in both EBN16,7 and EBN28 were identified; they encode for two highly 
homologous potassium (K+) channel subunits named Kv7.2 and Kv7.3, respectively. The 
Kv7 K+ channel subfamily also includes Kv7.1, which controls the repolarization phase 
of the cardiac action potential and is altered in the Long QT Syndrome-2;9 Kv7.4, which 
is mutated in some forms of autosomal dominant deafness;10 and Kv7.5.11 Kv7 channel 
subunits are characterized by the presence of six transmembrane segments (S1–S6). At 
most neuronal sites, heteromeric tetramerization of Kv7.2 and Kv7.3 subunits is thought 
to underlie most of the M-current,12 a widely-distributed K+ current characterized by low 
activation threshold, slow activation and deactivation kinetics, absence of inactivation, and 
regulation by Gq/11-coupled receptors.
Since the first identification of the disease-causing genes, several families affected by 
BFNS have been described and genotyped for Kv7.2 and Kv7.3 mutations; these are 
found in approximately 70% of the cases, suggesting the existence of additional loci.13 An 
updated list of the mutations identified in BFNS is given in Table 1. Collectively, these 
results reveal that Kv7.2 is a major locus for BFNS, being affected in more than 90% of 
the cases, with a penetrance of about 85%. Missense, non-sense and frameshift mutations 
leading to truncated or extended protein sequences have been described, with most of the 
families showing a different genetic alteration; while most missense mutations alter the 
sequence of the transmembrane region of the protein, the largest number of mutations 
fall within the long C-terminus domain. This region, beside embedding the molecular 
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Table 1 Overview of the available genetic, clinical and functional data from BFNS families
Kv7.2
 Amino Acid Change localization Clinical data (Beside BFnS) Functional effects reference
 M1V N‑terminus  — — 33
 M1T  — — 33
 Frameshift at K69  — — 33
 Frameshift at Q78  LCS+GCS — 34
 In‑frame deletion of S105 S1 — — 34
 S122L S2  FS later in life; seizures until 7 years Rightward shift in current voltage‑dependence  35 
    in the sub‑threshold region; decrease   
    in current activation kinetics 
 Splice site mutation at L129  — — 17
 Frameshift at S195 S2‑S3 linker — — 36
 A196V S4 — Rightward shift in current voltage‑dependence;  26 
    decrease in current activation kinetics; novel   
    prepulse‑dependence of current   
    activation kinetics 
 A196V/L197P  — Rightward shift in current voltage‑dependence;  26, 36 
    decrease in current activation kinetics 
 R207W  Myokymia Marked rightward shift in current voltage‑dependence;  23 
    dramatic decrease in current activation kinetics 
 R207Q  Myokymia Rightward shift in current voltage‑dependence;  24 
    decrease in current activation kinetics 
 M208V  GS between 4 and 7 years Small decrease in maximal current;  17 
    increased rate of channel deactivation 
 R214W  — Slight rightward shift in current voltage‑dependence;  25, 37 
    no effect on maximal current amplitude 
 H228Q S4‑S5 linker — — 17
 L243F S5 — — 17
 S247W  Therapy‑resistant seizures;  Markedly reduced maximal current  27 
   epileptic encephalopathy amplitude (dominant‑negative effect   
    on Kv7.2 channels) 
 S247X  CS; FS at three years — 35
 V250G  — — 36
 E254X  mild mental retardation; West syndrome Lack of functional homomeric channels;  20 
    markedly reduced current amplitude in   
    heteromeric channels 
 W269X S5‑S6 linker 1/7 late onset; 2/7 FS+GS in adulthood — 17
 G271V Pore BFIC — 38
 Frameshift at K283  5/19 GS between 21 and 45 years — 6
 Y284C  — Markedly reduced current amplitude 6, 25
 A306T S6 11/69 FS; GS between 1 and 16 years — 6
 Q323X C‑terminus 2/6 BECTS at 2 and 4 years Lack of functional homomeric channels;  17 
    marked reduction in current amplitude in   
    heteromeric channels 
 R333Q  — Reduction in current amplitude; Faster rate  17 
    of current deactivation 
 L339R  — — 36
 R353G  — Reduced interaction with CaM  33
 Splice site mutation at S373   LCS+GCS; 1 FS — 34
 S382X  late onset BFNS; 4/11 FS, GS until 10 years — 6
 Splice site mutation at N396  wide range of clinical manifestations,  — 39 
   with partial seizures later in life  
 Splice site mutation at L397   — — 40
 Frameshift at K398  GTCS — 41
 Splice site mutation at R406  — — 40
Continued
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determinants required for subunit assembly, also provides the attach-
ment site for a complex network of interacting molecules such as 
phosphatidylinositol 4,5-bisphosphate (PIP2), calmodulin (CaM), 
A-kinase-anchoring proteins (AKAPs), Ankyrin-G (Ank-G), and, 
possibly, pK-A and pK-C, having crucial functional consequences 
on channel behaviour and sub-cellular distribution14 (Fig. 1A). In 
heterologous expression systems, studies on the functional conse-
quences of these mutations have been carried out for a significant 
fraction of the described Kv7.2 and Kv7.3 mutations (Table 1), with 
consequences ranging from slight changes in channel behaviour to 
a complete ablation of channel function. The available evidence 
converges on the hypothesis that a slight (≈ 25%) decrease of the 
M-current is sufficient to cause BFNS; thus, haploinsufficiency 
seems to be the primary pathogenetic mechanism for BFNS. 
However, genotype-phenotype correlations may provide clues on the 
pathogenesis of the wide variety of neuropsychiatric manifestations 
often associated with BFNS in different families or family members.
One paradigmatic example is possibly provided by the association 
between BFNS and an EEG trait characterized by centrotemporal 
spikes (CTS), or benign rolandic epilepsy (BRE), the most common 
idiopathic partial epilepsy.15-17 Although the age-dependent CTS trait 
seems to segregate independently from Kv7.2,18 in the families where 
Table 1 Overview of the available genetic, clinical and functional data from BFNS families (continued)
 R448X  — 30% reduction in maximal current  17, 33, 36 
    amplitude in heteromeric channels 
 Splice site mutation at E509  — — 33
 Frameshift at Q494   — — 40
 Splice site mutation at D516  — — 40
 Frameshift at S522  late onset BFNS; 1/6 FS at 2 years — 6
 Frameshift at P534  — Lack of functional homomeric channels;  7 
    reduction maximal current amplitude of   
    heteromeric channels 
 Splice site mutation at C544  late onset BFNS — 6
 R553Q  — — 36
 K554N  2/4 therapy‑resistant seizures and  Slight rightward shift in current voltage‑dependence;  28 
   mental retardation no effect on maximal current amplitude 
 R581X  — — 17
 Splice site mutation at R588   — — 33
 R588X (intronic mutation)  1/11 seizures continued until 14 months of age;  — 42 
   photosensitive myoclonic epilepsy at    
   age 13 years; 1/11 mental retardation  
 L637R  — Increased interaction with CaM 33
 Frameshift at Y644 (+ 56aa)  In all patients, seizures persisted  — 21, 43 
   until 12–18 months  
 Frameshift at T653  — — 17
 Frameshift at P709 (+ 56aa)  1/3 CTS at 3 years; 1/3 GS later in life Lack of functional homomeric channels;  15, 19, 44 
    reduction in current amplitude of heteromeric   
    channels; decreased protein stability and   
    enhanced degradation 
 Frameshift at G866 (+ 56aa)  — Reduction of current amplitude in homomeric  22 
    and heteromeric channels 
 Frameshift at W867 (+ 57aa)  3/12 seizures continued until age 2, 3, 7 years Reduction in current amplitude;  17 
    Slight shift in activation voltage‑dependence;   
    slight acceleration of current deactivation 
Kv7.3
 Amino Acid Change localization Additional Clinical data (Beside BFnS) Functional effects reference
 D305G Pore — Reduced current amplitude of  17 
    heteromeric channels 
 W309R  — — 45
 G310V  — slight (20%) reduction in heteromeric channels current 8
 N468S  C‑terminus Three siblings affected by BFIC No effect; possibly a polymorphism 17
 N821S  Does not cosegregate with the disease No difference versus wt; possibly a  20 
    variant of unknown significance 
 nt c988t ? — — 46
LCS, lateral clonic seizures; GCS, generalized clonic seizures; FS, febrile seizures; GS, generalized seizures; CS, clonic seizures; BFIC, benign familial infantile convulsions; BECTS, benign epilepsy with centrotemporal 
spikes; GTCS, generalized tonic-clonic seizures; CTS, centrotemporal spikes. When necessary, amino acid numbering has been modified according to ref. 6, and is consistent with the longest variant “a” of Kv7.2 (872 
amino acids; GenBank AF033348).
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an association between BFNS and the CTS trait has been described, 
the CTS trait (or BRE) developed earlier than in classical rolandic 
epilepsy. Analysis of the functional consequences of Kv7.2 channels 
carrying the mutations found in families in which BFNS was followed 
by the appearance of the CTS trait, namely a complete truncation 
of the C-terminus (Q323X),17 or the substitution of the last 163 
amino acids within the same region (frameshift at P709),15 revealed 
a complete loss of function of mutant subunits. A CTS trait has been 
also found in the original family described by Rett and Teubel;1 inter-
estingly, in this family, the same mutation found by Coppola etal.15 
was identified.19 These results raise the intriguing possibility that 
specific Kv7.2 gene defects may be responsible for the early appear-
ance of BRE and, possibly, of various epilepsies or epilepsy-associated 
EEG traits. It is tempting to speculate that more dramatic functional 
consequences (such as a complete mutation-induced loss of channel 
function) maybe also responsible for more serious BFNS-associated 
clinical phenotypes, such as mild mental retardation and West 
syndrome,20 or delayed age of remission;21 this view seems to be 
supported by the observation that BFNS patients carrying more 
distal C-terminus mutations (frameshift at G866) which produced 
less dramatic consequences in functional expression studies, appear 
to be affected by classical BFNS with no atypical clinico-electrophysi-
ological features after the BFNS symptoms have disappeared.22
Two families in which BFNS was associated with generalized 
myokymia, a disease characterized by skeletal muscle spontaneous 
twitching resulting from hyper-excitability of the lower motor 
neurons, have been described (see refs. 23 and 24). Surprisingly, 
both families carried missense mutations in the same amino acid, 
namely the third arginine residue in the voltage-sensing S4 domain 
(R207W and R207Q, respectively). Functional studies revealed that 
the mutations did not lead to the loss of channel function, but rather 
to a dramatic rightward shift in the steady-state voltage-dependence 
of current activation, together with a marked decrease of current 
activation kinetics; as also shown in Figure 1B, the functional conse-
quences on channel gating produced by mutations neutralizing the 
charge at R207 are considerably more dramatic than those prompted 
by a similar BFNS-causing mutation affecting another charged 
residues in the S4 region (R214W),
25 both in homomeric and 
heteromeric configuration with Kv7.3 subunits, possibly suggesting 
a lesser involvement of the R214 residue in Kv7.2 voltage-sensing 
when compared to the R207 residue. Thus, subtle changes of Kv7.2 
gating properties can cause BFNS because of a decrease in M-current 
repolarizing ability in cortical neurons during early developmental 
stages; on the other hand, when more dramatic changes in the gating 
properties of Kv7.2 channels are triggered by the specific under-
lying mutation, the intrinsic excitability of spinal motor neurons 
is also affected, thus leading, in addition to BFNS, to involuntary 
myokymia. Noticeably, mutations in uncharged residues in the S4 
region can also cause BFNS because of peculiar changes in the gating 
properties of Kv7.2 channel subunits.26
BFNS is among the best-recognized disease model for 
 genetically-determined human epilepsies. The identification of 
Figure 1. (A) Schematic representation of a single Kv7.2 subunit. With respect to the drawing, relevant sites for functional modulation are shown below; 
the amino acid positions affected by the mutations discussed in the text and indicated in Table 1 are represented by blue circles and identified above 
the  drawing. AIS, Axon initial segment (B) Effect of the R207W and R214W mutations on homomeric Kv7.2 (left panel) and heteromeric Kv7.2 + Kv7.3 
(right panel) channel function. Current traces were recorded upon expression in Xenopus oocytes of the indicated subunit(s) in response to membrane 
 depolarization to +40 mV; holding potential: ‑90 mV. (For further experimental details, see ref. 25).
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disease-causing mutations in Kv7.2 and Kv7.3 K+ channel genes has 
allowed a clarification of the molecular pathogenesis of the disease 
and to explore the function of these genes in neuronal excitability. 
Nonetheless, several issues are yet to be resolved with regard to 
the evolution of the disease and its possible association with other 
convulsive manifestations or neuropsychological abnormalities, in 
order to bridge the existing gap between clinical characterization 
and functional studies. For example, clinical follow-up of BFNS 
family members often reveals more pronounced disease severity, 
with the occurrence of therapy-resistant epilepsies or epileptic 
encephalopathy.27,28 Electrophysiological analysis of the functional 
consequences of the disease-causing mutations has not revealed a 
strong genotype-phenotype correlation: in one case,27 the Kv7.2 
mutation (S247W) was able to reduce the channel currents by 
more than 50%, whereas in the other case28 (K554N) only a slight 
reduction in channel function was observed. However, it should be 
underlined that most of the in-vitro functional experiments often do 
not cover the full spectrum of alterations in channel function, which 
might be prompted by the underlying mutation. In fact, the latter 
mutation falls within the calmodulin binding site along the Kv7.2 
cytoplasmic C-terminus (Fig. 1A), next to a consensus sequence 
for pK-C-induced phosphorylation; whether the mutation impairs 
such regulation, which is crucial for channel function,29,30 is yet to 
be investigated.
Given these limitations, and despite the rarity of the disease, a 
tighter link between clinical/genetic characterization and functional 
consequences is crucial to further our comprehension of BFNS and 
BFNS-associated phenomena. To this aim, investigators should pay 
particular attention to provide full descriptions of the phenotypic 
characteristics of the disease in each individual family, directing their 
efforts at discriminating the age of onset of symptoms, the charac-
teristics and mode of onset of their convulsive episodes, response to 
available pharmacological therapy, and, in particular, the long-term 
evolution of the disease; moreover, functional studies should attempt 
to widen the range of techniques used to investigate the mutation-in-
duced disease mechanism, possibly in experimental contexts closer 
to the in vivo situation, such as upon expression of mutant channels 
in a neuronal environment.31 It can be anticipated that studies on 
the genotype-phenotype correlation in BFNS-affected patients may 
also boost research on Kv7 channels as pharmacological targets for 
hyper-excitability diseases.32
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